Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. 🚀 Unusual movers, 🎞️ market snapshot, and 💥 crucial news – we've got it all!

Happening Today

✓ 10:00 AM ET – NAHB Housing Market Index (Mar)

✓ 11:30 AM ET – 3-Month Bill Auction

✓ 11:30 AM ET – 6-Month Bill Auction

Daily Quote

In trading, the wise investor values consistency over quick wins and learns more from losses than gains.

PREMARKET SNAPSHOT 📈

Stock futures suggest a tepid start for the week; the Nasdaq 100 suffers the steepest decline, nearing a 1% drop.

SECTOR SNAPSHOT ✨

Energy leads (+0.23%) with Information Technology trailing (-1.29%). Consumer Discretionary, Health Care, and Communication Services see red. Others show minor changes.

Unusual Volume

📈 Verb Technology Company Inc (VERB) jumped 211.41% to $0.44 on a whopping 546.47 million shares traded after announcing its latest technological integration achievement with META.  

📈 Investors went wild, sending C3is Inc (CISS) stock declining -64.18% to $0.03 on a massive volume of 203.68 million shares. Nasdaq notified the company that its common stock, trading below $0.10 for ten straight days until March 14, 2024, will be delisted from The Nasdaq Capital Market.

📈 Abnormal activity shook Better Therapeutics Inc (BTTX), pushing it up 27.43% to $0.04 on a whopping 201.54 million shares traded. The company announced that it is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the Company.

📈 Bristol-Myers Squibb Co. (BMY) stock recently closed -0.29% lower at $52.34 on substantial volume of 123.59 million shares. This unusual activity came after the FDA has granted accelerated approval of Breyanzi® (lisocabtagene maraleucel; liso-cel).

📈 Geron Corp. (GERN) increase by 92.00% in a single trading session, with abnormally high trading volume of 111.71 million shares after the FDA committee approved imetelstat for treating anemia in certain MDS patients.

Premarket Movers

Important FDA 

Recently Announced

OptiNose Inc. (OPTN) received FDA approval for expanded use of XHANCE nasal spray in treating adults with chronic rhinosinusitis without nasal polyps on March 15, 2024. 

Johnson & Johnson (JNJ) underwent FDA panel review for expanded use of CARVYKTI in treating relapsed or refractory multiple myeloma patients, with the outcome still pending.

Bristol-Myers Squibb Co. (BMY) received a positive FDA panel recommendation for expanded use of Abecma in treating triple-class exposed relapsed or refractory multiple myeloma patients on March 15, 2024.

Announcing Today

Orchard Therapeutics plc (ORTX) eagerly anticipates FDA's verdict on OTL-200 for metachromatic leukodystrophy, with the decision currently pending as of March 18, 2024.

Upcoming this Week

Merck & Co Inc. (MRK) awaits FDA decision on Sotatercept for pulmonary arterial hypertension, outcome pending as of March 26, 2024.

Akebia Therapeutics, Inc. (AKBA) anticipates FDA verdict on Vadadustat for anemia in chronic kidney disease patients on dialysis, decision pending as of March 27, 2024.

Regeneron Pharmaceuticals (REGN) is in anticipation of the FDA decision on Odronextamab for adult patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma, with the outcome pending as of March 31, 2024.

Happy investing,

Maeve Grace
Editor In Cheif
Premium Trade Alerts

 Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.